38
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Natriuretic regulation of extracellular fluid volume homeostasis includes suppression of the renin-angiotensin-aldosterone system, pressure natriuresis, and reduced renal nerve activity, actions that concomitantly increase urinary Na + excretion and lead to increased urine volume. The resulting natriuresis-driven diuretic water loss is assumed to control the extracellular volume. Here, we have demonstrated that urine concentration, and therefore regulation of water conservation, is an important control system for urine formation and extracellular volume homeostasis in mice and humans across various levels of salt intake. We observed that the renal concentration mechanism couples natriuresis with correspondent renal water reabsorption, limits natriuretic osmotic diuresis, and results in concurrent extracellular volume conservation and concentration of salt excreted into urine. This water-conserving mechanism of dietary salt excretion relies on urea transporter–driven urea recycling by the kidneys and on urea production by liver and skeletal muscle. The energy-intense nature of hepatic and extrahepatic urea osmolyte production for renal water conservation requires reprioritization of energy and substrate metabolism in liver and skeletal muscle, resulting in hepatic ketogenesis and glucocorticoid-driven muscle catabolism, which are prevented by increasing food intake. This natriuretic-ureotelic, water-conserving principle relies on metabolism-driven extracellular volume control and is regulated by concerted liver, muscle, and renal actions.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.

          First conceptualized as a mechanism for the mitochondrial transport of long-chain fatty acids in the early 1960s, the carnitine palmitoyltransferase (CPT) system has since come to be recognized as a pivotal component of fuel homeostasis. This is by virtue of the unique sensitivity of the outer membrane CPT I to the simple molecule, malonyl-CoA. In addition, both CPT I and the inner membrane enzyme, CPT II, have proved to be loci of inherited defects, some with disastrous consequences. Early efforts using classical approaches to characterize the CPT proteins in terms of structure/function/regulatory relationships gave rise to confusion and protracted debate. By contrast, recent application of molecular biological tools has brought major enlightenment at an exponential pace. Here we review some key developments of the last 20 years that have led to our current understanding of the physiology of the CPT system, the structure of the CPT isoforms, the chromosomal localization of their respective genes, and the identification of mutations in the human population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immune cells control skin lymphatic electrolyte homeostasis and blood pressure.

            The skin interstitium sequesters excess Na+ and Cl- in salt-sensitive hypertension. Mononuclear phagocyte system (MPS) cells are recruited to the skin, sense the hypertonic electrolyte accumulation in skin, and activate the tonicity-responsive enhancer-binding protein (TONEBP, also known as NFAT5) to initiate expression and secretion of VEGFC, which enhances electrolyte clearance via cutaneous lymph vessels and increases eNOS expression in blood vessels. It is unclear whether this local MPS response to osmotic stress is important to systemic blood pressure control. Herein, we show that deletion of TonEBP in mouse MPS cells prevents the VEGFC response to a high-salt diet (HSD) and increases blood pressure. Additionally, an antibody that blocks the lymph-endothelial VEGFC receptor, VEGFR3, selectively inhibited MPS-driven increases in cutaneous lymphatic capillary density, led to skin Cl- accumulation, and induced salt-sensitive hypertension. Mice overexpressing soluble VEGFR3 in epidermal keratinocytes exhibited hypoplastic cutaneous lymph capillaries and increased Na+, Cl-, and water retention in skin and salt-sensitive hypertension. Further, we found that HSD elevated skin osmolality above plasma levels. These results suggest that the skin contains a hypertonic interstitial fluid compartment in which MPS cells exert homeostatic and blood pressure-regulatory control by local organization of interstitial electrolyte clearance via TONEBP and VEGFC/VEGFR3-mediated modification of cutaneous lymphatic capillary function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1.

              In skeletal muscle, protein levels are determined by relative rates of protein synthesis and breakdown. The balance between synthesis and degradation of intracellular components determines the overall muscle fiber size. AMP-activated protein kinase (AMPK), a sensor of cellular energy status, was recently shown to increase myofibrillar protein degradation through the expression of MAFbx and MuRF1. In the present study, the effect of AMPK activation by AICAR on autophagy was investigated in muscle cells. Our results show that FoxO3a transcription factor activation by AMPK induces the expression of the autophagy-related proteins LC3B-II, Gabarapl1, and Beclin1 in primary mouse skeletal muscle myotubes and in the Tibialis anterior (TA) muscle. Time course studies reveal that AMPK activation by AICAR leads to a transient nuclear relocalization of FoxO3a followed by an increase of its cytosolic level. Moreover, AMPK activation leads to the inhibition of mTORC1 and its subsequent dissociation of Ulk1, Atg13, and FIP200 complex. Interestingly, we identify Ulk1 as a new interacting partner of AMPK in muscle cells and we show that Ulk1 is associated with AMPK under normal conditions and dissociates from AMPK during autophagy process. Moreover, we find that AMPK phosphorylates FoxO3a and Ulk1. In conclusion, our data show that AMPK activation stimulates autophagy in skeletal muscle cells through its effects on the transcriptional function of FoxO3a and takes part in the initiation of autophagosome formation by interacting with Ulk1. Here, we present new evidences that AMPK plays a crucial role in the fine tuning of protein expression programs that control skeletal muscle mass. Copyright © 2011 Wiley Periodicals, Inc.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Clin Invest
                J. Clin. Invest
                J Clin Invest
                The Journal of Clinical Investigation
                American Society for Clinical Investigation
                0021-9738
                1558-8238
                17 April 2017
                1 May 2017
                1 August 2017
                : 127
                : 5
                : 1944-1959
                Affiliations
                [1 ]Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
                [2 ]Department of Medicine II, University Medical Center Mainz, Mainz, Germany.
                [3 ] Renal Division, Department of Medicine, and
                [4 ]Department of Physiology, Emory University, Atlanta, Georgia, USA.
                [5 ]Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
                [6 ]Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA.
                [7 ]Junior Research Group 2, Interdisciplinary Center for Clinical Research, University Clinic Erlangen, Erlangen, Germany.
                [8 ]Experimental and Clinical Research Center, Charité Medical Faculty and the Max-Delbrueck Center for Molecular Medicine, Berlin, Germany.
                [9 ]Institute of Clinical Microbiology and Hygiene, University Clinic Regensburg and University Regensburg, Regensburg, Germany.
                [10 ]Department of Pediatrics, University Clinic Erlangen, Erlangen, Germany.
                [11 ]Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
                Author notes
                Address correspondence to: Jens Titze, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2213 Garland Avenue, P435F MRBIV, Nashville, Tennessee 37232, USA. Phone: 615.343.1401; E-mail: jens.m.titze@ 123456vanderbilt.edu .

                Authorship note: K. Kitada and S. Daub contributed equally to this work.

                Article
                PMC5409074 PMC5409074 5409074 88532
                10.1172/JCI88532
                5409074
                28414295
                33a6e79a-afcb-4145-89c2-313f8b733b28
                Copyright © 2017, American Society for Clinical Investigation
                History
                : 17 May 2016
                : 17 February 2017
                Categories
                Research Article

                Comments

                Comment on this article